Proteasome Inhibitors for Cancer Therapy - Page 2

Articles in this Topic Discussions in this Topic

Page 2

Jul 30, 2003

Pancreatic cancer - this disease progresses very rapidly, and is invariably fatal. The mean survival time after diagnosis is 3 to 6 months. A small Phase I pilot study using proteasome inhibitor appears very promising. A combination of bortezomib with gemcitabin resulted in a significantly increased survival time.

Prostate cancer - This cancer is relatively easy to cure while it is confined to the prostate gland. However, after it has spread, treatment with chemotherapy has proven difficult, and treatment to block male hormone secretion is only partially effective. A Phase I study treating advanced prostate cancer patients with a combination of bortezomib and docetaxel gave promising results.

Colon and esophageal cancers - preliminary Phase I clinical trials indicated that many patients showed stability of their cancers and clinical responses.

References

1. Adams, J. Development of the Proteasome Inhibitor PS-341. The Oncologist, Vol. 7, No. 1, pp. 9-16 (February 2002)

2. Adams, J., et. al. Proteasome Inhibition: A New Pathway in Cancer Therapy. Medscape CME, June 13, 2003

Go To Page: 1 2

The copyright of the article Proteasome Inhibitors for Cancer Therapy - Page 2 in Cancer Treatment is owned by . Permission to republish Proteasome Inhibitors for Cancer Therapy - Page 2 in print or online must be granted by the author in writing.